Could a vaccine keep triple negative breast cancer from returning?

NCT ID NCT05455658

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This phase II trial tests a DNA-based vaccine called STEMVAC in 33 people with early-stage triple negative breast cancer (stages IB-III). The vaccine is designed to train the immune system to recognize and attack cancer cells that express certain proteins. Participants also receive an immune booster (sargramostim). The main goal is to see if the vaccine triggers a strong immune response, not yet to measure cancer recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
STEMVAC (a DNA plasmid vaccine) and sargramostim (an immune booster)
What this could lead to
If successful, this could lead to a vaccine that helps prevent triple negative breast cancer from coming back after initial treatment.
What could go wrong
This is a small, early-phase trial (33 people) focused on immune response, not yet on preventing recurrence. The vaccine may not produce a strong enough immune reaction or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IB BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21287, United States

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.